Kaplan-Meier estimated median OS and 1-y survival comparisons within preselected treatment subgroups
| . | No. of patients . | OS . | 1-y survival . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median . | Difference . | HR . | 95% CI . | P . | ||||||||
| Months . | 95% CI . | Months . | 95% CI . | % . | 95% CI . | Difference . | 95% CI . | |||||
| Preselected for BSC only | 89 | |||||||||||
| Azacitidine | 44 | 5.8 | 3.6-9.7 | 2.1 | –1.0-5.2 | 0.60 | 0.38-0.95 | .0288 | 30.3 | 17.5-44.2 | 11.7 | –6.3-29.8 |
| BSC | 45 | 3.7 | 2.8-5.7 | 18.6 | 8.7-31.4 | |||||||
| Preselected for LDAC | 312 | |||||||||||
| Azacitidine | 154 | 11.2 | 8.8-13.4 | 4.8 | 1.7-7.9 | 0.90 | 0.70-1.16 | .4270 | 48.5 | 40.3-56.2 | 14.5 | 3.5-25.5 |
| LDAC | 158 | 6.4 | 4.8-9.1 | 34.0 | 26.6-41.6 | |||||||
| Preselected for IC | 87 | |||||||||||
| Azacitidine | 43 | 13.3 | 7.2-19.9 | 1.1 | –5.4-7.6 | 0.85 | 0.52-1.38 | .5032 | 55.8 | 39.8-69.1 | 4.9 | –16.2-26.0 |
| IC | 44 | 12.2 | 7.5-15.1 | 50.9 | 35.2-64.6 | |||||||
| . | No. of patients . | OS . | 1-y survival . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median . | Difference . | HR . | 95% CI . | P . | ||||||||
| Months . | 95% CI . | Months . | 95% CI . | % . | 95% CI . | Difference . | 95% CI . | |||||
| Preselected for BSC only | 89 | |||||||||||
| Azacitidine | 44 | 5.8 | 3.6-9.7 | 2.1 | –1.0-5.2 | 0.60 | 0.38-0.95 | .0288 | 30.3 | 17.5-44.2 | 11.7 | –6.3-29.8 |
| BSC | 45 | 3.7 | 2.8-5.7 | 18.6 | 8.7-31.4 | |||||||
| Preselected for LDAC | 312 | |||||||||||
| Azacitidine | 154 | 11.2 | 8.8-13.4 | 4.8 | 1.7-7.9 | 0.90 | 0.70-1.16 | .4270 | 48.5 | 40.3-56.2 | 14.5 | 3.5-25.5 |
| LDAC | 158 | 6.4 | 4.8-9.1 | 34.0 | 26.6-41.6 | |||||||
| Preselected for IC | 87 | |||||||||||
| Azacitidine | 43 | 13.3 | 7.2-19.9 | 1.1 | –5.4-7.6 | 0.85 | 0.52-1.38 | .5032 | 55.8 | 39.8-69.1 | 4.9 | –16.2-26.0 |
| IC | 44 | 12.2 | 7.5-15.1 | 50.9 | 35.2-64.6 | |||||||